中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 6
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(6): 1304-1307

Liver inflammation and fibrosis in HBV-infected patients with a low viral load

DOI: 10.3969/j.issn.1001-5256.2023.06.008
  • 1.

    Department of Difficult Hepatology, Ganzhou Fifth People's Hospital, Ganzhou, Jiangxi 341000, China

  • 2.

    Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Research funding:

Science and Technology Fund Project of Jiangxi Provincial Health Commission (202212322);

Ganzhou Science and Technology Bureau Fund Project (GZ2020ZSF294)

More Information
  • Corresponding author: JIANG Manlei, lffjml@163.com (ORCID: 0000-0003-0971-6219)
  • Received Date: 2022-10-27
  • Accepted Date: 2022-12-12
  • Published Date: 2023-06-20
    Abstract
  •   Objective  To investigate liver inflammation and fibrosis in patients with chronic HBV infection with a low viral load.  Methods  Among the HBsAg-positive patients who attended Ganzhou Fifth People's Hospital from April 2019 to June 2022, 41 patients with 20 IU/mL < HBV DNA < 2 000 IU/mL were selected and underwent the examinations of blood biochemistry, liver stiffness measurement (LSM), and liver biopsy to clarify liver inflammation and fibrosis. Liver inflammation was analyzed according to HBV DNA, alanine aminotransferase (ALT), LSM, and age. The chi-square test was used for comparison of categorical data between groups.  Results  Among the 41 patients, 15 (36.59%) had liver inflammation grade ≥G2 and/or liver fibrosis stage ≥S2. Among these 15 patients, 11 (73.33%) had an HBV DNA level of > 200-2 000 IU/mL and 4 (26.67%) had an HBV DNA level of 20-200 IU/mL; the patients with G2 liver inflammation accounted for 73.33% (11/15), and those with S2 liver fibrosis accounted for 46.67% (7/15); the patients with ALT ≤30 U/L accounted for 46.67% (7/15); the patients aged ≥30 years accounted for 86.66% (13/15); the patients with LSM > 17 kPa accounted for 6.67% (1/15), those with an LSM value of 12.4-17 kPa accounted for 46.67% (7/15), and those with an LSM value of 9.4-12.4 kPa accounted for 33.33% (5/15).  Conclusion  Patients with chronic HBV infection and low-level viremia have a relatively high risk of progression of inflammation and fibrosis. ALT level cannot be used as a basis for antiviral therapy in HBV-infected people with a low viral load. LSM based on transient elastography can be used as a noninvasive test to screen for CHB patients with a low viral load, and antiviral therapy should be considered when HBV-infected patients with a low viral load have an age of > 30 years and an LSM value of > 9.4 kPa persistently.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    SETO WK, LO YR, PAWLOTSKY JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324. DOI: 10.1016/S0140-6736(18)31865-8.
    [2]
    HUTIN Y, NASRULLAH M, EASTERBROOK P, et al. Access to treatment for hepatitis B virus infection - worldwide, 2016[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(28): 773-777. DOI: 10.15585/mmwr.mm6728a2.
    [3]
    ZHANG R, TANG YY, YU Q, et al. Analysis on ten-year data of individualized programs to prevent mother-to-child transmission of hepatitis B virus[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2021, 15(5): 303-310. DOI: 10.3877/cma.j.issn.1674-1358.2021.05.003.

    张荣, 唐雍艳, 喻茜, 等. 个体化方案阻断乙型肝炎病毒母婴传播十年数据分析[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15(5): 303-310. DOI: 10.3877/cma.j.issn.1674-1358.2021.05.003.
    [4]
    CAO XZ, YI W, LIU XM, et al. The immune response and influencing factor of hepatitis B virus vaccine on 3-year-old children born to mothers infected with HBV[J/OL]. Chin J Liver Dis (Electronic Version), 2022, 14(2): 57-62. DOI: 10.3969/j.issn.1674-7380.2022.02.009.

    曹秀贞, 易为, 刘雪梅, 等. HBV感染母亲所生儿童3岁时乙肝疫苗免疫应答情况及影响因素[J/OL]. 中国肝脏病杂志(电子版), 2022, 14(2): 57-62. DOI: 10.3969/j.issn.1674-7380.2022.02.009.
    [5]
    LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
    [6]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [7]
    China Hepatitis Prevention and Control Foundation, Infectious Diseases Branch of Chinese Medical Association, Hepatology Branch of Chinese Medical Association and Hepatology Professional Committee of Chinese Research Hospital Association. Expert consensus on transient elastography for the diagnosis of liver fibrosis (2018 updated edition)[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [8]
    LOK AS, MCMAHON BJ. Chronic hepatitis B[J]. Hepatology, 2007, 45(2): 507-539. DOI: 10.1002/hep.21513.
    [9]
    LIAW YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int, 2009, 29(Suppl 1): 100-107. DOI: 10.1111/j.1478-3231.2008.01941.x.
    [10]
    FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0.
    [11]
    HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724.
    [12]
    MA JW, ZHAI YZ. Progress on treatment of immune tolerance phase of hepatitis B virus infection[J/OL]. Chin J Liver Dis(Electronic Version), 2022, 14(2): 32-36. DOI: 10.3969/j.issn.1674-7380.2022.02.005.

    马俊雯, 翟永贞. 乙型肝炎病毒感染免疫耐受期治疗进展[J/OL]. 中国肝脏病杂志(电子版), 2022, 14(2): 32-36. DOI: 10.3969/j.issn.1674-7380.2022.02.005.
    [13]
    Hepatology Branch of Chinese Medical Association. Expert opinion on expanding antiviral therapy for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060.

    中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060.
    [14]
    WANG C, WANG C, DEUBNER H, et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection[J]. Hepatology, 2005, 42(Suppl 1): A573.
    [15]
    ZHUANG H. Should chronic hepatitis B be treated in the uncertain phase?[J]. J Clin Hepatol, 2021, 37(9): 2033-2036. DOI: 10.3969/j.issn.1001-5256.2021.09.007.

    庄辉. 不确定期慢性乙型肝炎应否治疗?[J]. 临床肝胆病杂志, 2021, 37(9): 2033-2036. DOI: 10.3969/j.issn.1001-5256.2021.09.007.
    [16]
    SUN Y, CHANG J, LIU X, et al. Mortality trends of liver diseases in mainland China over three decades: an age-period-cohort analysis[J]. BMJ Open, 2019, 9(11): e029793. DOI: 10.1136/bmjopen-2019-029793.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (497) PDF downloads(75) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return